A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Atavistik Bio, Inc
Atavistik Bio, Inc
K36 Therapeutics, Inc.
Cedars-Sinai Medical Center
AstraZeneca
Pathos AI, Inc.
University of Washington
Marengo Therapeutics, Inc.
Novartis
Revolution Medicines, Inc.
Endocyte
Stanford University
UroGen Pharma Ltd.
Poseida Therapeutics, Inc.
VA Greater Los Angeles Healthcare System
University Health Network, Toronto
University Medical Center Groningen
Promontory Therapeutics Inc.
Steba Biotech S.A.
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Aragon Pharmaceuticals, Inc.
Revolution Medicines, Inc.
Region Skane
Revolution Medicines, Inc.
Seoul National University Bundang Hospital
Advanced Accelerator Applications
Steba Biotech S.A.
Steba Biotech S.A.
University of Oulu
Endo Pharmaceuticals
Dendreon
Life Molecular Imaging SA
UroGen Pharma Ltd.
Steba Biotech S.A.
Medical Enterprises Europe B.V.
Medical Enterprises Europe B.V.